1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pakistan Pharmaceuticals and Healthcare Report Q4 2016

Pakistan Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 108 pages

Includes 3 FREE quarterly updates

BMI View:

Pakistan's pharmaceutical market will remain a low priority for innovative drugmakers.Downward price pressures on pharmaceutical prices coupled with uncertainty surrounding the country'spolicy direction impinge on potential commercial opportunities, while a fragmented procurement systemhinders efforts to establish sales strategy. These factors result in an unattractive medicines market that willincentivise multinational pharmaceutical firms to invest in other emerging markets such as China orIndonesia where the risk and rewards are more favourable.

Headline Expenditure Projections

- Pharmaceuticals: PKR252bn (USD2.5bn) in 2015 to PRK274bn (USD2.6bn) 2016; +8.5% in localcurrency terms and +6.1% in US dollar terms.

- Healthcare: PKR740bn (USD7.2bn) in 2015 to PKR810bn (USD7.7bn) in 2016; +9.4% in localcurrency terms and +7.1% in US dollar terms.Risk/Reward IndexPakistan's Pharmaceutical Risk/Reward Index (RRI) score for Q416 is 41.7 out of 100. This places it in the16th out of 19 other markets in the Asia Pacific region. This low score is driven by the below averageindustry rewards with a low spending per capita in USD (scoring 1.2 out of 12) as well modest sector valuegrowth (6.0 out of 12.0). Similarly the country's instability further drags down the country's risk score (12.9out of 35).

Table Of Contents

Pakistan Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Pakistan 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Pakistan 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Pakistan 2012-2020) 17
Table: Government Healt Expenditure Trends, Historical Data And Forecasts (Pakistan 2010-2018) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Pakistan 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 26
OTC Medicines Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Pakistan 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Pakistan 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Pakistan 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index - Q4 2016 33
Pakistan Risk/Reward Index 40
Rewards 40
Risks 40
Regulatory Review 42
Regulatory Developments 45
Intellectual Property Issues 45
Pricing Regime 45
Reimbursement Regime 47
Market Overview 49
Healthcare Sector 50
Table: Healthcare Resources (Pakistan 2010-2015) 52
Table: Healthcare Personnel (Pakistan 2010-2015) 52
Table: Healthcare Activity (Pakistan 2010-2015) 53
Research and Development 53
Clinical Trials 54
Epidemiology 55
Table: Diabetic Patients' Education Level and Compliance Levels 57
Table: Estimated Number Of New Cases Of Cancer In Pakistan 58
Table: Frequency Of Information Provided To Patients As A Percentage Of Total Cases 58
Competitive Landscape 60
Research-Based Industry 60
Table: Multinational Market Activity 60
Generic Drugmakers 61
Table: PPMA As Of 2015 62
Pharmaceutical Distribution 65
Company Profile 67
Abbott Laboratories 67
Efroze Chemical Industries 71
Ferozsons Laboratories 74
Getz Pharma 77
GlaxoSmithKline 80
Hilton Pharma 84
Novartis 86
Pfizer 89
Sanofi-Aventis 92
Searle Pakistan Limited 95
Demographic Forecast 97
Table: Population Headline Indicators (Pakistan 1990-2025) 98
Table: Key Population Ratios (Pakistan 1990-2025) 98
Table: Urban/Rural Population and Life Expectancy (Pakistan 1990-2025) 99
Table: Population By Age Group (Pakistan 1990-2025) 99
Table: Population By Age Group % (Pakistan 1990-2025) 100
Glossary 102
Methodology 104
Pharmaceutical Expenditure Forecast Model 104
Healthcare Expenditure Forecast Model 104
Notes On Methodology 105
Risk/Reward Index Methodology 106
Index Overview 107
Table: Pharmaceutical Risk/Reward Index Indicators 107
Indicator Weightings 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.